Study power is the holy grail of clinical trials, setting drug developers on the quickest path to market — but nonadherence causes costly detours.
When participants do not take their medication as specified in the study protocol, it can result in underestimated drug efficacy, delay the approval of investigational products, and contribute to rising costs.
Without mitigation, then, medication nonadherence can have a significant impact on clinical trial return on investment (ROI).The scale of the problem
A staggering 80% of clinical studies fail to finish recruitment on time, and 20% of these are delayed for at least six months1 – and every single day of delay to market can cost between $600,000 and $8 million in lost revenue.2
Taking control of adherence is one way to recoup costs and improve ROI. Studies show that each patient involved in a Phase 3 tria…